455 related articles for article (PubMed ID: 21586296)
1. Estrogen receptors and gonadal steroids in vulnerability and protection of dopamine neurons in a mouse model of Parkinson's disease.
Al-Sweidi S; Morissette M; Bourque M; Di Paolo T
Neuropharmacology; 2011 Sep; 61(4):583-91. PubMed ID: 21586296
[TBL] [Abstract][Full Text] [Related]
2. Oestrogen receptors and signalling pathways: implications for neuroprotective effects of sex steroids in Parkinson's disease.
Al Sweidi S; Sánchez MG; Bourque M; Morissette M; Dluzen D; Di Paolo T
J Neuroendocrinol; 2012 Jan; 24(1):48-61. PubMed ID: 21790809
[TBL] [Abstract][Full Text] [Related]
3. Effect of oestrogen receptors on brain NMDA receptors of 1-methyl-4-phenyl-1,2,3,6-tetrahydropyridine mice.
Al-Sweidi S; Morissette M; Di Paolo T
J Neuroendocrinol; 2012 Nov; 24(11):1375-85. PubMed ID: 22672467
[TBL] [Abstract][Full Text] [Related]
4. Role of estrogen receptors in neuroprotection by estradiol against MPTP toxicity.
Morissette M; Jourdain S; Al Sweidi S; Menniti FS; Ramirez AD; Di Paolo T
Neuropharmacology; 2007 Jun; 52(7):1509-20. PubMed ID: 17420033
[TBL] [Abstract][Full Text] [Related]
5. Oestrogens prevent loss of dopamine transporter (DAT) and vesicular monoamine transporter (VMAT2) in substantia nigra of 1-methyl-4-phenyl-1,2,3,6-tetrahydropyridine mice.
Jourdain S; Morissette M; Morin N; Di Paolo T
J Neuroendocrinol; 2005 Aug; 17(8):509-17. PubMed ID: 16011487
[TBL] [Abstract][Full Text] [Related]
6. Estrogen receptors and lesion-induced response of striatal dopamine receptors.
Al Sweidi S; Morissette M; Rouillard C; Di Paolo T
Neuroscience; 2013 Apr; 236():99-109. PubMed ID: 23357113
[TBL] [Abstract][Full Text] [Related]
7. Neuroprotective properties of 17beta-estradiol, progesterone, and raloxifene in MPTP C57Bl/6 mice.
Callier S; Morissette M; Grandbois M; Pélaprat D; Di Paolo T
Synapse; 2001 Aug; 41(2):131-8. PubMed ID: 11400179
[TBL] [Abstract][Full Text] [Related]
8. Estrogen receptors modulate striatal metabotropic receptor type 5 in intact and MPTP male mice model of Parkinson's disease.
Al-Sweidi S; Morissette M; Di Paolo T
J Steroid Biochem Mol Biol; 2016 Jul; 161():84-91. PubMed ID: 26873133
[TBL] [Abstract][Full Text] [Related]
9. Dehydroepiandrosterone (DHEA) such as 17beta-estradiol prevents MPTP-induced dopamine depletion in mice.
D'Astous M; Morissette M; Tanguay B; Callier S; Di Paolo T
Synapse; 2003 Jan; 47(1):10-4. PubMed ID: 12422368
[TBL] [Abstract][Full Text] [Related]
10. Implication of the phosphatidylinositol-3 kinase/protein kinase B signaling pathway in the neuroprotective effect of estradiol in the striatum of 1-methyl-4-phenyl-1,2,3,6-tetrahydropyridine mice.
D'Astous M; Mendez P; Morissette M; Garcia-Segura LM; Di Paolo T
Mol Pharmacol; 2006 Apr; 69(4):1492-8. PubMed ID: 16434614
[TBL] [Abstract][Full Text] [Related]
11. Estrogen reduces BDNF level, but maintains dopaminergic cell density in the striatum of MPTP mouse model.
Tripanichkul W; Gerdprasert O; Jaroensuppaperch EO
Int J Neurosci; 2010 Jul; 120(7):489-95. PubMed ID: 20583901
[TBL] [Abstract][Full Text] [Related]
12. Neuroprotective effects of genistein on dopaminergic neurons in the mice model of Parkinson's disease.
Liu LX; Chen WF; Xie JX; Wong MS
Neurosci Res; 2008 Feb; 60(2):156-61. PubMed ID: 18054104
[TBL] [Abstract][Full Text] [Related]
13. Estrogen attenuates the MPTP-induced loss of dopamine neurons from the mouse SNc despite a lack of estrogen receptors (ERalpha and ERbeta).
Shughrue PJ
Exp Neurol; 2004 Dec; 190(2):468-77. PubMed ID: 15530885
[TBL] [Abstract][Full Text] [Related]
14. The 5α-reductase inhibitor Dutasteride but not Finasteride protects dopamine neurons in the MPTP mouse model of Parkinson's disease.
Litim N; Bourque M; Al Sweidi S; Morissette M; Di Paolo T
Neuropharmacology; 2015 Oct; 97():86-94. PubMed ID: 26006269
[TBL] [Abstract][Full Text] [Related]
15. Telmisartan attenuates MPTP induced dopaminergic degeneration and motor dysfunction through regulation of α-synuclein and neurotrophic factors (BDNF and GDNF) expression in C57BL/6J mice.
Sathiya S; Ranju V; Kalaivani P; Priya RJ; Sumathy H; Sunil AG; Babu CS
Neuropharmacology; 2013 Oct; 73():98-110. PubMed ID: 23747572
[TBL] [Abstract][Full Text] [Related]
16. Broad neuroprotective profile of nicotinamide in different mouse models of MPTP-induced parkinsonism.
Anderson DW; Bradbury KA; Schneider JS
Eur J Neurosci; 2008 Aug; 28(3):610-7. PubMed ID: 18702732
[TBL] [Abstract][Full Text] [Related]
17. Intervention with exercise restores motor deficits but not nigrostriatal loss in a progressive MPTP mouse model of Parkinson's disease.
Sconce MD; Churchill MJ; Greene RE; Meshul CK
Neuroscience; 2015 Jul; 299():156-74. PubMed ID: 25943481
[TBL] [Abstract][Full Text] [Related]
18. Low dose pramipexole is neuroprotective in the MPTP mouse model of Parkinson's disease, and downregulates the dopamine transporter via the D3 receptor.
Joyce JN; Woolsey C; Ryoo H; Borwege S; Hagner D
BMC Biol; 2004 Oct; 2():22. PubMed ID: 15473914
[TBL] [Abstract][Full Text] [Related]
19. Effect of MPTP-induced denervation on basal ganglia GABA(B) receptors: correlation with dopamine concentrations and dopamine transporter.
Calon F; Lavertu N; Lemieux AM; Morissette M; Goulet M; Grondin R; Blanchet PJ; Bédard PJ; Di Paolo T
Synapse; 2001 Jun; 40(3):225-34. PubMed ID: 11304760
[TBL] [Abstract][Full Text] [Related]
20. Neuroprotection in Parkinson models varies with toxin administration protocol.
Anderson DW; Bradbury KA; Schneider JS
Eur J Neurosci; 2006 Dec; 24(11):3174-82. PubMed ID: 17156378
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
